Shorter infusion times for cancer immunotherapy drugs
Treatments studied
Part of Cancer clinical trials.
This trial tests if giving common immunotherapy drugs over a shorter time is safe. It may mean less time in the clinic for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are starting treatment with one of these drugs: nivolumab, pembrolizumab, ipilimumab, bevacizumab, trastuzumab, durvalumab, or atezolizumab
- You have no known history of allergic reactions to this type of drug
- You can and are willing to sign a consent form
- You are not taking other research medications in the last 4 weeks
- You do not receive your drugs through a central line (like a port-a-cath)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the timing of a standard immunotherapy combination for advanced melanoma that cannot be removed by surgery or has spread. It aims to understand how timing affects treatment results.
This trial tests a very short course of immunotherapy (nivolumab) before standard surgery for patients with certain types of advanced or hard-to-treat skin cancer (cutaneous squamous cell carcinoma). The goal is to see if this approach can reduce the need for extensive or disfiguring surgery.
This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.
This early trial compares how often two immune system medicines—nivolumab and pembrolizumab—are given for advanced or metastatic cancers. It aims to see which dosing interval is workable and safe for people needing treatment.
This trial tests whether giving a shorter course of immunotherapy after surgery can help prevent melanoma from coming back. It is for people with high-risk melanoma who have had the cancer fully removed.
This study looks at how certain cancer drugs (called immune checkpoint inhibitors) interact with other medicines in the body. It aims to help doctors understand how to safely combine these treatments.
Hear when a new Oncology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.